A case study of a 56-year-old man with lymphoid blast phase chronic myeloid leukemia (CML) harboring the T315I mutation in the BCR-ABL fusion gene demonstrated that anti-CD19 CAR T cell therapy following dasatinib treatment induced complete remission [220]. This evidence concerns the gene CD19 and chronic myelogenous leukemia, BCR-ABL1 positive.